ESMO 2018 | Checkpoint inhibitors for head and neck cancer in the definitive setting?

Barbara Burtness

Barbara Burtness, MD, of Yale School of Medicine, New Haven, CT, talks about the current survival benefit of early pembrolizumab exposure in recurrent/metastatic head and neck squamous cell carcinoma (HNSCCO and its potential applications in definitive treatment. Its combination with chemo-radiation, along with other immune checkpoint inhibitors are currently being studied. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video